Who is sponsoring NCT07071727?

NCT07071727 is sponsored by The Netherlands Cancer Institute.

What drugs are being tested in NCT07071727?

Interventions in NCT07071727: Preoperative radiotherapy.

What condition does NCT07071727 study?

NCT07071727 studies Sarcoma of Soft Tissue, Sarcoma, Sarcoma, Soft Tissue.

Is NCT07071727 still recruiting?

NCT07071727 is currently recruiting now. Last updated 19 February 2026.

Last reviewed 2026-02-19 · How we verify

NCT07071727: SCOPES II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas

Recruiting now NA Last updated 19 February 2026

What this trial tests

NA trial testing Preoperative radiotherapy in Sarcoma of Soft Tissue in 150 participants. Currently enrolling.

Timeline

11 December 2025

Primary endpoint
1 November 2028

1 November 2033

Quick facts

Lead sponsor	The Netherlands Cancer Institute
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	11 December 2025
Primary completion	1 November 2028
Estimated completion	1 November 2033
Sites	6 locations across Netherlands

Drugs / interventions tested

Preoperative radiotherapy

Conditions studied

Sarcoma of Soft Tissue — all drugs for Sarcoma of Soft Tissue →
Sarcoma — all drugs for Sarcoma →
Sarcoma, Soft Tissue — all drugs for Sarcoma, Soft Tissue →

Sponsor

The Netherlands Cancer Institute

Who can join

18 and older, any sex, with Sarcoma of Soft Tissue or Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Based upon the preliminary data derived from first SCOPES clinical trial and the results of patients treated during the recent COVID-19 pandemic, patients with soft tissue sarcomas (STS) can be preoperatively irradiated in a modestly hypofractionated schedule of 14 x 3 Gy. From a toxicity and efficacy point of view, this regimen equals the outcomes after a conventionally fractionated regimen of 25 x 2 Gy in five weeks. Moreover, the rationale for investigating (modest) hypofractionation in the clinic comes both from a logistic point of view (patient convenience and a lower pressure on radiotherapy equipment), form prior phase II clinical evidence and from (cellular) radiobiological observations. There is phase II trial evidence suggesting that even more (ultra-) hypofractionation to 5 x 6 Gy is also safe and effective. Within this study, patients will be randomized to receive either the modestly hypofractionated conventional schedule of 14 x 3 Gy or an even shorter preoperative regimen of 5 x 6 Gy, in the hypothesis that both the postoperative wound complication rate until 120 days after surgery, as well as the local control probability at two years are comparable in both arms.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol.
Shang P, Li M, Zhang X, Zhu D, et al · · 2026 · PMID 42022357 · DOI 10.1002/pro6.70046

Verify or expand the search:

Other trials of Preoperative radiotherapy

Trials testing the same drug.

NCT06739655 — Preoperative Radiation Therapy and Immediate Breast Reconstruction · NA · recruiting
NCT05357846 — PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) · Phase 3 · recruiting
NCT05512286 — Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction · NA · recruiting
NCT03822936 — Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma · Phase 2 · terminated

Other The Netherlands Cancer Institute trials

Trials by the same sponsor.

NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting
NCT07281508 — Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07071727 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
Last refreshed: 19 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07071727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing